Keylicon Biosciences Inc
Publicly observedBrookline, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Brookline | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Keylicon Biosciences Inc | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | UXSKUT48A7W3 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant7 Sept 2026Publicly observed
NIH SBIR/STTR award: Improving the Stability of saRNA LNP Formulations To Overcome Cold Chain Challenges
USD 400,000.00 · National Institute of Biomedical Imaging and Bioengineering · Source: NIH RePORTER (opens in a new tab)
- Grant1 Sept 2026Publicly observed
NIH SBIR/STTR award: Extended In Situ Production of Glucocerebrosidase (GCase) for the Treatment of Gaucher Disease
USD 400,000.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Aug 2026Publicly observed
NIH SBIR/STTR award: Low Dose Multivalent Influenza Vaccine via Modified Self-Amplifying RNA
USD 314,363.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant20 Jul 2026Publicly observed
NIH SBIR/STTR award: Multivalent Vaccine Against Lyme Disease via Modified Self-Amplifying RNA
USD 314,363.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.